Targeted agents indicated for autoimmune diseases

Targeted agents indicated for autoimmune diseases

Within the autoimmune space, payers face difficult challenges in decision making. This category has non-exhaustive and non-exclusive populations, making management by indication burdensome. To further complicate the category, indications can be subdivided even further...Read more...
MKO Minute – Rise of Gene Therapy

MKO Minute – Rise of Gene Therapy

This has been an exciting week for gene therapy in the U.S. market. With the approval of Novartis’ novel CAR-T gene therapy, and a launch price below analyst expectations, there is uncertainty around the pricing expectations for future pipeline agents. How will...Read more...
Management and Budget Impact

Management and Budget Impact

With the evolution of payer management in different specialty classes, MKO has been tracking management priority and budget impact using our M Tracker. M Tracker has revealed a significant change in oncology and HCV management in the first half of 2017. Here is a...Read more...
MKO Minute – When Cures Become Commodities

MKO Minute – When Cures Become Commodities

The price wars in Hepatitis C continues as both Gilead and AbbVie launch their respective products into a market with a diminishing number of new patient starts. Which of the companies’ pricing strategies will prevail? Click HERE see full size image...Read more...